Literature DB >> 6111584

Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs.

M Toru, O Matsuda, K Makiguchi, K Sugano.   

Abstract

A 63-year-old woman with diagnosis of Parkinson's disease developed an unusual symptom complex which consisted of extrapyramidal symptoms, disturbances of consciousness, diaphoresis, fever, and increased serum creatine phosphokinase following the discontinuation of large doses of combined antiparkinsonian drugs. After the patient's condition did not improve with the first 14 days of treatment consisting of intravenous fluids and antibiotics, a trial administration of L-dopa and carbidopa brought about definite clinical improvement. The symptoms strongly resembled neuroleptic malignant syndrome which is often a serious complication of antipsychotic drugs. The symptoms and the treatment of the present case suggest that dopaminergic hypoactivity in the brain may be an important factor in antiparkinsonian drug withdrawal syndrome and that similar neurochemical mechanisms may exist in neuroleptic malignant syndrome.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6111584     DOI: 10.1097/00005053-198105000-00011

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  20 in total

Review 1.  Clinical features, pathogenesis and management of drug-induced rhabdomyolysis.

Authors:  C Köppel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Mar-Apr

2.  Case files of the program in medical toxicology at brown university: amantadine withdrawal and the neuroleptic malignant syndrome.

Authors:  Eric Brantley; Jamieson Cohn; Kavita Babu
Journal:  J Med Toxicol       Date:  2009-06

3.  Muscle pathology in the neuroleptic malignant syndrome.

Authors:  D T Martin; M Swash
Journal:  J Neurol       Date:  1987-12       Impact factor: 4.849

Review 4.  Clinical management of neuroleptic malignant syndrome.

Authors:  V L Susman
Journal:  Psychiatr Q       Date:  2001

5.  Levodopa withdrawal syndrome identical to neuroleptic malignant syndrome.

Authors:  W R Gibb; D N Griffith
Journal:  Postgrad Med J       Date:  1986-01       Impact factor: 2.401

6.  Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome.

Authors:  J Kornhuber; M Weller
Journal:  J Neural Transm Gen Sect       Date:  1993

7.  Risk factors for neuroleptic malignant syndrome.

Authors:  M J Akpaffiong
Journal:  J Natl Med Assoc       Date:  1992-09       Impact factor: 1.798

8.  Hyperthermic syndromes and impairment of the dopaminergic system: a clinical study.

Authors:  L Figà-Talamanca; C Gualandi
Journal:  Ital J Neurol Sci       Date:  1989-02

9.  Acute Akinesia, an unusual complication in Parkinson's Disease: a case report.

Authors:  Marco Simonetto; Laura Ferigo; Luca Zanet; Livio Capus; Lucia Antonutti; Marino Zorzon; Gilberto Pizzolato
Journal:  Neurol Sci       Date:  2008-07-09       Impact factor: 3.307

10.  Malignant syndrome in Parkinson's disease without dopaminergic drug withdrawal.

Authors:  C J Suresh Chandran
Journal:  Ann Indian Acad Neurol       Date:  2008-10       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.